Category Archives: Europe

M&As: Past, Present, and Future

Pharmaceutical Technology’s Faiz Kermani looks at the long history of pharma mergers and finds no sign of the trend slowing down. It was suggested that in one week of April the total value of various rumored deals was of the order of US$100 billion, illustrating how cash-rich major pharmaceutical companies are. Many of the larger […]
Also posted in Deals, Emerging Markets, Global, Guest Blog, R&D, Strategy | Tagged , , | Leave a comment

60 Years of Pharma Regulation in Europe

European regulation of pharmaceuticals has, since the foundation of the European Union around 60 years ago, been a story of medicines being controlled in a collaboration between regulators at the EU and national levels. In recent years, this collaboration has been extended to involve not just the regulators themselves but also other stakeholders such as […]
Also posted in Regulatory, Safety | Tagged , , | Leave a comment

Biosimilar Development in Europe: Ten Years On

The European Union established the first legal regulatory guidelines for biosimilars in 2005. The first biosimilar, Omnitrope, a version of somatropin, was approved in April 2006. To date, the EU has approved 19 applications in total (two were withdrawn after authorization so 17 are now marketed) and continues to update its guidelines, general and product-specific, […]
Also posted in Biotech, Regulatory | Tagged , | Leave a comment

Primary Care Diabetes Prescriptions Cost UK Over £2 Million a Day

Prescriptions to manage diabetes in primary care in the UK cost the NHS an average of £2.2 million ($3.7 m) every day in 2013-14, according to a report from the Health and Social Care Information Centre (HSCIC). The report, Prescribing for Diabetes, also shows the Net Ingredient Cost (NIC)  for managing diabetes was £803.1 million ($1,347 m) in 2013–14. […]
Also posted in Global, healthcare | Tagged , | Leave a comment

Pharma & Biotech Most Active Sector in UK M&As

The pharma, medical and biotech (PMB) sector, driven by the Novartis’s £8.6bn acquisition of GlaxoSmithKline’s oncology division, was the most active industry in UK M&A in H1 2014, with a 26.9% market share (£10.1bn), according to Mergermarket’s latest deal round-up. However M&A activity targeting the United Kingdom — standing at £37.5bn in H1 2014 — represented […]
Also posted in Deals | Tagged , , , , | Leave a comment
  • Categories

  • Meta